Mutually symbiotic alliances can often lead to great medicines
Advancing the frontier of any new field is rarely an individual pursuit, but this is especially true in biotechnology. To that end F1 is collaborating—and seeking out new partnerships—with those who share our mission of providing breakthrough, yet accessible, global cancer solutions.
F1 provides an experienced blend of innovative discovery and translational medicine within a framework of quality standards and regulatory science. Our comprehensive, data-driven approach to candidate design and selection provides an optimized and efficient process to select the best CAR composition for a given indication amongst hundreds of thousands of rationally designed combinations, while applying equal innovation to technologies that enable scalability and global patient access to our solutions.
- Shanghai PerHum Therapeutics Co., Ltd.
BioAtla develops novel cancer therapeutics that meet critical needs including improved safety and the treatment of previously undruggable cancers. BioAtla’s revolutionary patented platform for developing conditionally active therapeutics yields antibodies (as well as other biologics) that can be activated or inactivated under defined physiological conditions. Read more here.
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai PerHum Therapeutics Co. was formed for the express purpose of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. With key academic collaborations in Shanghai, GMP cell processing facilities have been developed to support clinical research. Additionally, PerHum recently acquired a lentivirus manufacturing facility in Shenzhen China, to enable the development of F1 Oncology’s serum-free suspension lentiviral manufacturing technology for clinical development of CCT3 programs. Read more about PerHum here.